NEXT-GENERATION, CYTOKIN-BASED IMMUNOTHERAPEUTICS

ingineeon's mission is to bring breakthrough medical innovations to patients that need them most. To achieve this, the start-up develops advanced cytokine-based immunotherapeutics. The current pipeline comprises first-in-class biologics in infectious diseases, inflammatory diseases, and oncology. As a spin-off from the Technical University of Munich, ingineeon's goal is to become a clinical stage company in the coming few years.


The management team of ingineeon: